Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology

키워드

참고문헌 (55)

1. 김경민, "Medication Related Osteonecrosis of the Jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons", 대한골대사학회지, 22(4), pp.151~165 (2015), 대한골대사학회
2. Adnane L, "Sorafenib(BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF", MEK, PDGFR in tumor vasculature, pp.Methods Enzymol, 2006[DOI]
3. Sun J, "The multi-targeted kinase inhibitor sunitinib induces apoptosis in colon cancer cells via PUMA", PLoS One, 7, pp.e43158~ (2012)
4. Ayllon J, "Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies : cumulative toxicity profile", Ann Oncol, 20, pp.600~601 (2009)
5. Beuselinck B, "Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases", Br J Cancer, 107, pp.1665~1671 (2012)
6. Bozas G, "Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib", Onkologie, 33, pp.321~323 (2010)
7. Hoefert S, "Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw : presentation of three cases", Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 110, pp.463~469 (2010)
8. Agrillo A, "Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib : two case reports", Eur Rev Med Pharmacol Sci, 16, pp.952~957 (2012)
9. van Cann T, "Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors", Support Care Cancer, 26, pp.869~878 (2018)
10. Koch FP, "Osteonecrosis of the jaw related to sunitinib", Oral Maxillofac Surg, 15, pp.63~66 (2011)
11. Fleissig Y, "Sunitinib related osteonecrosis of jaw : a case report", Oral Surg Oral Med Oral Pathol Oral Radiol, 113, pp.e1~e3 (2012)
12. Garuti F, "Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma", Tumori, 102(Suppl 2), pp.S69~S70 (2016)
13. Smidt-Hansen T, "Combination of zoledronic acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma", J Oral Maxillofac Surg, 71, pp.1532~1540 (2013)
14. Schindler T, "Structural mechanism for STI-571 inhibition of abelson tyrosine kinase", Science, 289, pp.1938~1942 (2000)
15. Dewar AL, "Imatinib inhibits the in vitro development of the monocyte", macrophage lineage from normal human bone marrow progenitors, 2003, pp.17, 1713~1721
16. Massimo Viviano, "A rare case of osteonecrosis of the jaw related to imatinib", 대한구강악안면외과학회지, 43(2), pp.120~124 (2017), 대한구강악안면외과학회
17. Abel Mahedi Mohamed H, "Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort", Oral Surg Oral Med Oral Pathol Oral Radiol, 125, pp.157~163 (2018)
18. Shen G, "Mammalian target of rapamycin as a therapeutic target in osteoporosis", J Cell Physiol, 233, pp.3929~3944 (2018)
19. Dowling RJ, "Dissecting the role of mTOR : lessons from mTOR inhibitors", Biochim Biophys Acta, 1804, pp.433~439 (2010)
20. Indo Y, "Metabolic regulation of osteoclast differentiation and function", J Bone Miner Res, 28, pp.2392~2399 (2013)
21. Simone V, "Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells", BMC Cancer, 15, pp.692~ (2015)
22. Kim DW, "Osteonecrosis of the jaw related to everolimus : a case report", Br J Oral Maxillofac Surg, 51, pp.e302~e304 (2013)
23. Yamamoto D, "Osteonecrosis of the jaw associated with everolimus : a case report", Mol Clin Oncol, 6, pp.255~257 (2017)
24. Giancola F, "Osteonecrosis of the jaw related to everolimus and bisphosphonate: a unique case report?", Ann Stomatol (Roma), 4(Suppl 2), pp.20~21 (2013)
25. Nifosì AF, "Osteonecrosis of the jaw in a patient treated with denosumab and temsirolimus", SAJ Case Rep, 4, pp.401~ (2017)
26. Rajabi M, "The role of angiogenesis in cancer treatment", Biomedicines, 5, pp.E34~ (2017)
27. Magremanne M, "Unusual bevacizumab-related complication of an oral infection", J Oral Maxillofac Surg, 71, pp.53~55 (2013)
28. Hartl DM, "Bevacizumab-induced laryngeal necrosis", Ann Oncol, 23, pp.276~278 (2012)
29. Mailliez A, "Nasal septum perforation : a side effect of bevacizumab chemotherapy in breast cancer patients", Br J Cancer, 103, pp.772~775 (2010)
30. Estilo CL, "Osteonecrosis of the jaw related to bevacizumab", J Clin Oncol, 26, pp.4037~4038 (2008)
31. Greuter S, "Bevacizumabassociated osteonecrosis of the jaw", Ann Oncol, 19, pp.2091~2092 (2008)
32. Serra E, "Bevacizumab-related osteneocrosis of the jaw", Int J Immunopathol Pharmacol, 22, pp.1121~1123 (2009)
33. Wynn RL, "Bevacizumab(Avastin) : an anti-angiogenic drug associated with osteonecrosis of the jaw", Gen Dent, 59, pp.410~413 (2011)
34. Dişel U, "A case report of bevacizumab-related osteonecrosis of the jaw : old problem, new culprit", Oral Oncol, 48, pp.e2~e3 (2012)
35. Katsenos S, "Osteonecrosis of the jaw in a patient with advanced non-small-cell lung cancer receiving bevacizumab", Arch Bronconeumol, 48, pp.187~220 (2012)
36. Pakosch D, "Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab", Oral Maxillofac Surg, 17, pp.303~306 (2013)
37. Brunamonti Binello P, "Osteonecrosis of the jaws and bevacizumab therapy : a case report", Int J Immunopathol Pharmacol, 25, pp.789~791 (2012)
38. Christodoulou C, "Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone", Oncology, 76, pp.209~211 (2009)
39. Aragon-Ching JB, "Higher incidence of Osteonecrosis of the Jaw(ONJ)in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents", Cancer Invest, 27, pp.221~226 (2009)
40. Guarneri V, "Bevacizumab and osteonecrosis of the jaw : incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer", Breast Cancer Res Treat, 122, pp.181~188 (2010)
41. McArthur HL, "Osteonecrosis of the jaw (ONJ) among intravenous (IV)bisphosphonate- and", or bevacizumab-treated patients (pts) at Memorial Sloan-Kettering Cancer Center (MSKCC), 2008, pp.26(15 Suppl), 9588~
42. Francini F, "Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab", J Am Dent Assoc, 142, pp.506~513 (2011)
43. Hopp RN, "Osteonecrosis after administration of intravitreous bevacizumab", J Oral Maxillofac Surg, 70, pp.632~635 (2012)
44. Yuan F, "Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor", vascular permeability factor antibody, 1996, pp.93, 14765~14770
45. Bettini G, "Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process", BMJ Case Rep, 2012, pp.bcr2012007~ (2012)
46. Santos-Silva AR, "Osteonecrosis of the mandible associated with bevacizumab therapy", Oral Surg Oral Med Oral Pathol Oral Radiol, 115, pp.e32~e36 (2013)
47. Chu QS, "Aflibercept(AVE0005) : an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors", Expert Opin Biol Ther, 9, pp.263~271 (2009)
48. Mawardi H, "Osteonecrosis of the jaw associated with ziv-aflibercept", J Gastrointest Oncol, 7, pp.E81~E87 (2016)
49. Ponzetti A, "Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil:attention to oral district", Tumori, 102(Suppl 2), pp.S74~S77 (2016)
50. Langer LF, "Update on anti-CTLA-4 antibodies in clinical trials", Expert Opin Biol Ther, 7, pp.1245~1256 (2007)
51. Kong YY, "Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand", Nature, 402, pp.304~309 (1999)
52. Owosho AA, "Osteonecrosis of the jaw a new complication related to Ipilimumab", Oral Oncol, 51, pp.e100~e101 (2015)
53. Hujoel P, "Osteonecrosis of the jaw and oral hygiene : a case-control study from Condor Dental PBRN", J Dent Hyg, 86, pp.32~33 (2012)
54. Bonacina R, "Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw : a review of 282 patients", J Can Dent Assoc, 77, pp.b147~ (2011)
55. Khan AA, "Diagnosis and management of osteonecrosis of the jaw : a systematic review and international consensus", J Bone Miner Res, 30, pp.3~23 (2015)

관련 논문AI추천